Literature DB >> 24151321

Immune activation and the role of TLRs and TLR agonists in the pathogenesis of HIV-1 infection in the humanized mouse model.

J Judy Chang1, Marcus Altfeld.   

Abstract

Immune activation plays a critical role in HIV-1 pathogenesis, but the pathways that are responsible for HIV-1-associated immune activation are not well understood. Recent advances in the development of a humanized mouse model for HIV-1 infection might provide new approaches to study the mechanisms of HIV-1 associated immune activation, and to test interventions aimed at reducing HIV-1 pathogenesis.

Entities:  

Keywords:  HIV-1; TLR; humanized mouse; innate immunity; pathogenesis

Mesh:

Substances:

Year:  2013        PMID: 24151321      PMCID: PMC3807976          DOI: 10.1093/infdis/jit402

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment.

Authors:  Karl-Dimiter Bissig; Stefan F Wieland; Phu Tran; Masanori Isogawa; Tam T Le; Francis V Chisari; Inder M Verma
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

2.  Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.

Authors:  Wei Jiang; Michael M Lederman; Peter Hunt; Scott F Sieg; Kathryn Haley; Benigno Rodriguez; Alan Landay; Jeffrey Martin; Elizabeth Sinclair; Ava I Asher; Steven G Deeks; Daniel C Douek; Jason M Brenchley
Journal:  J Infect Dis       Date:  2009-04-15       Impact factor: 5.226

3.  Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques.

Authors:  Levelle D Harris; Brian Tabb; Donald L Sodora; Mirko Paiardini; Nichole R Klatt; Daniel C Douek; Guido Silvestri; Michaela Müller-Trutwin; Ivona Vasile-Pandrea; Cristian Apetrei; Vanessa Hirsch; Jeffrey Lifson; Jason M Brenchley; Jacob D Estes
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

4.  Exposure to HIV-1-encoded Toll-like receptor 8 ligands enhances monocyte response to microbial encoded Toll-like receptor 2/4 ligands.

Authors:  Marianne W Mureith; J Judy Chang; Jeffrey D Lifson; Thumbi Ndung'u; Marcus Altfeld
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

Review 5.  Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts.

Authors:  Donald L Sodora; Jonathan S Allan; Cristian Apetrei; Jason M Brenchley; Daniel C Douek; James G Else; Jacob D Estes; Beatrice H Hahn; Vanessa M Hirsch; Amitinder Kaur; Frank Kirchhoff; Michaela Muller-Trutwin; Ivona Pandrea; Jörn E Schmitz; Guido Silvestri
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

6.  Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.

Authors:  Angela Meier; J Judy Chang; Ellen S Chan; Richard B Pollard; Harlyn K Sidhu; Smita Kulkarni; Tom Fang Wen; Robert J Lindsay; Liliana Orellana; Donna Mildvan; Suzane Bazner; Hendrik Streeck; Galit Alter; Jeffrey D Lifson; Mary Carrington; Ronald J Bosch; Gregory K Robbins; Marcus Altfeld
Journal:  Nat Med       Date:  2009-07-13       Impact factor: 53.440

7.  Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys.

Authors:  Steven E Bosinger; Qingsheng Li; Shari N Gordon; Nichole R Klatt; Lijie Duan; Luoling Xu; Nicholas Francella; Abubaker Sidahmed; Anthony J Smith; Elizabeth M Cramer; Ming Zeng; David Masopust; John V Carlis; Longsi Ran; Thomas H Vanderford; Mirko Paiardini; R Benjamin Isett; Don A Baldwin; James G Else; Silvija I Staprans; Guido Silvestri; Ashley T Haase; David J Kelvin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

8.  Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation.

Authors:  Jeffrey A Martinson; Carlos J Montoya; Xiomara Usuga; Rollie Ronquillo; Alan L Landay; Seema N Desai
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

9.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

10.  High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.

Authors:  Veronica D Gonzalez; Karolin Falconer; Kim G Blom; Olle Reichard; Birgitte Mørn; Alex Lund Laursen; Nina Weis; Annette Alaeus; Johan K Sandberg
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

View more
  4 in total

1.  Recent advances in humanized mice: accelerating the development of an HIV vaccine.

Authors:  Andrew M Tager; Michael Pensiero; Todd M Allen
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

2.  Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals.

Authors:  Ling Wang; Juan Zhao; Jun P Ren; Xiao Y Wu; Zheng D Morrison; Mohamed A Elgazzar; Shun B Ning; Jonathan P Moorman; Zhi Q Yao
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

Review 3.  Human Immunodeficiency Virus 1 and Type I Interferons-Where Sex Makes a Difference.

Authors:  Susanne Maria Ziegler; Marcus Altfeld
Journal:  Front Immunol       Date:  2017-09-28       Impact factor: 7.561

4.  Sulfasalazine as an Immunomodulator of the Inflammatory Process during HIV-1 Infection.

Authors:  Manuel G Feria-Garzón; María T Rugeles; Juan C Hernandez; Jorge A Lujan; Natalia A Taborda
Journal:  Int J Mol Sci       Date:  2019-09-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.